Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL) recall — FDA D-0723-2021
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
Overview of recall records associated with PAI Holdings, LLC. dba Pharmaceutical Associates Inc., including dates, categories and classifications where available.
Classification mix: Class II: 3.
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
This page summarizes recall records in which the official source identifies PAI Holdings, LLC. dba Pharmaceutical Associates Inc. as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.